The newly approved mosunetuzumab for relapsed/refractory follicular lymphoma improves clinic efficiency and patient experience, says Zahra Mahmoudjafari, PharmD, MBA, BCOP. She also explained how the ...
“Insulin injections remain a daily burden for many patients,” said Associate Professor Shingo Ito. “Our peptide-based platform offers a new route to deliver insulin orally and may be applicable to ...
Leqvio (inclisiran) may cause injection site reactions, including bruising, pain, discoloration, itchiness, and a burning or prickling sensation at the injection site. In addition to injection site ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results